Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-31719 MOLINA HEALTHCARE, INC. (Exact name of registrant as specified in its charter) De ...

Nathan Rich ThatÂ's great color. Thanks guys. George, we couldnÂ't hear the first part of your question. Are you talking about Medicare Advantage? Molina Healthcare, Inc. (NYSE:MOH) Q2 2023 Earnings Conference Call July 27, 2023 8:00 AM ET Conference Call Participants Good day, and welcome to the Molina Healthcare Second Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note, todayÂ's event is being recorded. Good morning, and welcome to Moli ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-31719 MOLINA HEALTHCARE, INC. (Exact name of registrant as specified in its charter) Delawar ...

Molina Healthcare, Inc. (NYSE:MOH) Q1 2023 Earnings Conference Call April 27, 2023 8:00 AM ET Company Participants Conference Call Participants Operator I would now like to turn the conference over to Joe Krocheski, Senior Vice President, Investor Relations. Please go ahead, sir. Good morning, and welcome to Molina Healthcare's first quarter 2023 earnings call. Joining me today are Molina's President and CEO, Joe Zubretsky; and our CFO, Mark Keim. A press release announcing our first quarter earnings was di ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-31719 MOLINA HEALTHCARE, INC. (Exact name of registrant as specified in its charter) Delawa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 1-31719 MOLINA HEALTHCARE, INC. (Exact name of registrant as specified in its charter) Delaware 13-4204626 (State or other jurisdiction of (I.R.S. Employer incorporation o ...

Company Participants Josh Raskin - Nephron Research A.J. Rice - Credit Suisse Justin Lake - Wolfe Research Calvin Sternick - JPMorgan Scott Fidel - Stephens Michael Hall - Morgan Stanley Stephen Baxter - Wells Fargo Nathan Rich - Goldman Sachs Gary Taylor - Cowen Steven Valiquette - Barclays Kevin Fischbeck - Bank of America David Windley - Jefferies Joe Krocheski Molina Healthcare, Inc. (NYSE:MOH) Q4 2022 Earnings Conference Call February 9, 2023 8:00 AM ET Conference Call Participants Good morning, and we ...

Financial Data and Key Metrics - Q3 2022 adjusted earnings per diluted share were $4.36, representing 54% YoY growth [9] - Consolidated medical care ratio (MCR) for Q3 was 88.4%, adjusted G&A ratio was 6.9%, and pretax margin was 4.3% [9] - Year-to-date MCR was 87.9%, adjusted G&A ratio was 6.9%, and pretax margin was 4.5%, in line with long-term targets [10] - Full-year 2022 premium revenue guidance increased by $500 million to $30.5 billion, with adjusted EPS guidance raised to at least $17.75 [14][36] Business Line Performance - Medicaid, representing 80% of revenue, reported a year-to-date MCR of 88.2%, reflecting strong medical cost management [11] - Medicare, representing 12% of revenue, reported a year-to-date MCR of 87.4%, in line with long-term targets despite COVID-related cost pressures [12] - Marketplace, representing 7% of revenue, is on track to return to profitability in 2022, with a Q3 MCR of 86.3% [13][30] Market Performance - Medicaid rate environment remains stable, with COVID costs tempering and strong execution on medical cost management [11] - Medicare niche serving low-income members continues to grow organically, with a year-to-date MCR of 87.4% [12] - Marketplace strategy focuses on stability, with no ambitious growth targets, and is expected to achieve mid-single-digit pretax margins [68][69] Strategy and Industry Competition - The company is executing a long-term growth strategy, with recent RFP wins in California, Iowa, and Nebraska expected to add $5.8 billion in annual premium revenue and $3 EPS at full run rate [15][17] - The company is preparing for significant expansion in California, with a 15-month build-out plan to handle new membership growth [17] - The company remains confident in its ability to win additional state contracts, with ongoing RFP submissions and business development initiatives [19] Management Commentary on Operating Environment and Future Outlook - Management highlighted strong Q3 performance, with premium revenue growth and realization of embedded earnings from 2021 [9] - The company expects 2023 to be a year of scaling operations for new revenue growth, with one-time nonrecurring expenses of $0.75 per share [22] - For 2024, the company anticipates premium revenue growth drivers, including organic growth, RFP wins, and acquisitions, leading to at least $37 billion in premium revenue [24] Other Important Information - The company has a strong balance sheet, with $298 million in parent company cash and substantial debt capacity to support growth strategies [33] - The company expects to achieve full run rate target margins by 2025, with significant fixed cost leverage from new contract wins [21][54] Q&A Session Summary Question: Preparation for LA County contract implementation - The company is confident in its ability to scale operations for the LA County contract, leveraging its 40-year presence in California and existing infrastructure [45] Question: Components of $1.7 billion organic growth - Organic growth is driven by a combination of membership and rate growth, with 3-4% annual growth expected, primarily in Medicaid and Medicare [49][50] Question: Margin ramp-up on new contract wins - The company expects new contract wins to achieve a 4% pretax margin, with conservative assumptions on fixed cost leverage and potential rate adjustments [53][54] Question: COVID and flu impact on utilization - The company maintains its outlook for $2.50 per share in COVID-related costs, with a normal flu season expected to cost $40 million+ [57][58] Question: Rate environment and Medicaid premium returns - The rate environment remains stable, with traditional processes for establishing cost baselines and trends [61][62] Question: Marketplace margins and growth strategy - The company aims for mid-single-digit pretax margins in Marketplace, with no significant growth expected due to strategic pricing for margin rather than market share [68][69] Question: Redetermination impact and recapture potential - The company expects $1.6 billion in revenue loss from redeterminations, split evenly between 2023 and 2024, with potential upside from recapturing members in Marketplace [73][74] Question: Embedded earnings power and redetermination dynamics - The company clarified its embedded earnings power, with $5.75 per share expected by 2025, and no significant margin impact anticipated from redeterminations [76][77][82] Question: LA County contract protest scenarios - The company is preparing for full implementation of the LA County contract, with no speculation on potential outcomes of ongoing protests [89][93] Question: RFP success factors and transferability to future RFPs - The company attributes its RFP success to a well-developed business unit with a playbook focused on state-specific needs and referenceable national capabilities [96][98] Question: Marketplace strategy amid market exits - The company does not expect significant membership growth from market exits, as it has priced for margin rather than market share [99][102] Question: Potential for Marketplace growth in California - The company sees potential for Marketplace growth in California but has not included it in current estimates, focusing first on Medicaid implementation [104][105] Question: M&A environment and capital allocation - The company remains active in M&A, with a robust pipeline and ample capital capacity to support growth through acquisitions and organic expansion [108][110][111] Question: Tailwinds and headwinds for 2023 - The company highlighted potential tailwinds from embedded earnings, organic growth, operational catalysts, and rising interest rates, with headwinds from redeterminations and pharmacy carve-outs [115][117] Question: Medicare Advantage growth outlook - The company expects low-teens growth in Medicare Advantage, focusing on low-income niches and leveraging its Medicaid footprint [121][122]

Molina Healthcare, Inc. (NYSE:MOH) Q2 2022 Earnings Conference Call July 28, 2022 8:00 AM ET Company Participants Joe Krocheski - Senior Vice President of Investor Relations Joe Zubretsky - President and Chief Executive Officer Mark Keim - Chief Financial Officer Conference Call Participants Josh Raskin - Nephron Research Matthew Borsch - BMO Capital Markets Stephen Baxter - Wells Fargo A.J. Rice - Credit Suisse Nathan Rich - Goldman Sachs Kevin Fischbeck - Bank of America Michael Hall - Morgan Stanley Geor ...

Molina Healthcare, Inc. (NYSE:MOH) Q1 2022 Earnings Conference Call April 27, 2022 8:00 AM ET Company Participants Joe Krocheski ??? Senior Vice President-Investor Relations Joe Zubretsky ??? President and Chief Executive Officer Mark Keim ??? Chief Financial Officer Conference Call Participants Ben Rossi ??? BMO Capital Markets Kevin Fischbeck ??? Bank of America Steven Valiquette ??? Barclays Justin Lake ??? Wolfe Research Nathan Rich ??? Goldman Sachs Michael Hall ??? Morgan Stanley A. J. Rice ??? Credit ...